Carboxy Methyl Lysine anticorps
Aperçu rapide pour Carboxy Methyl Lysine anticorps (ABIN1105660)
Antigène
Voir toutes Carboxy Methyl Lysine (CML) AnticorpsHôte
Clonalité
Conjugué
Application
Clone
-
-
Réactivité croisée (Details)
- Species reactivity (tested):Human, Multispecies cross reactant.
-
Purification
- Protein G Chromatography
-
Immunogène
- Carboxy Methyl Lysine (CML)-KLH
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 0.1 mg/mL
-
Buffer
- PBS, 0.02 % Sodium Azide, 0.1 % BSA
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C
-
Stockage commentaire
- Store undiluted at 2-8 °C.
-
-
- Carboxy Methyl Lysine (CML)
-
Autre désignation
- Carboxy Methyl Lysine
-
Classe de substances
- Amino Acid
-
Sujet
- CML is known to be formed from the oxidation of both carbohydrates and lipids. This makes CML a biomarker of general oxidative stress. Carboxymethyl-lysine (CML) is a well-characterized glycoxidation product that accumulates in tissues with age, and its rate of accumulation is accelerated in diabetes. Glycoxidation products are a subset of advanced glycation endproducts (AGEs) that are formed by the nonenzymatic glycation and subsequent irreversible oxidation of proteins. Oxidative stress and protein modification have been implicated in the pathogenesis of the chronic complications of diabetes, including nephropathy and atherosclerosis. The accumulation of CML in long-lived tissue such as skin collagen reflects oxidative stress over an extended period of the life-span, and has been shown to be greater in patients with diabetic complications than those without complications.Synonyms: CML, Carboxymethyl-lysine
Antigène
-